The surgical robot developer will use the series B financing, co-led by SinoPharm, to support it through its application for market clearance.
SinoPharm Capital, the corporate venturing arm of pharmaceutical company SinoPharm has co-led an $18m series B round for US-based surgical robot developer Virtual Incision with venture capital firm Bluestem Capital.
PrairieGold Venture Partners also invested in the round alongside undisclosed other investors. Bluestem Capital and PraireGold had previously participated in an $11.2m financing round for the company in 2015 and co-led its $2m series A round in 2010.
Spun out of University of Nebraska in 2006, Virtual Incision is…
